OPTIMIZATION OF TREATMENT STRATEGIES FOR CARDIORENAL SYNDROME IN PATIENTS WITH CHRONIC HEART FAILURE

Chronic heart failure (CHF) and cardiorenal syndrome (CRS) are major global health concerns due to their increasing prevalence and high morbidity rates. This study evaluates the effectiveness of sacubitril/valsartan therapy in comparison to valsartan monotherapy in CHF patients with CRS. A total of 70 patients aged 55–70 years with NYHA class II–III heart failure and stage III chronic kidney disease were analyzed. Patients were divided into two groups: Group 1 received sacubitril/valsartan (200 mg/day), and Group 2 received valsartan (160 mg/day). Clinical, laboratory, and instrumental assessments were conducted over a 90-day period. The results demonstrated that sacubitril/valsartan significantly improved cardiac function, renal hemodynamics, and overall patient quality of life compared to valsartan alone. The findings suggest that sacubitril/valsartan may serve as a superior therapeutic option for CHF patients with CRS, providing both cardioprotective and nephroprotective benefits.